Balanced news tone
News Sentiment
IART sentiment intelligence
Integra LifeSciences Holdings news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-1.1% over one week, +16.4% over four weeks, trend active, and below fair value.
Integra (IART) Shows Fast-paced Momentum But Is Still a Bargain Stock
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Integra (IART) Shows Fast-paced Momentum But Is Still a Bargain Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 12:55
- Source
- Market source
Integra LifeSciences: New Beginning (NASDAQ:IART)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 05:37
- Source
- Seeking Alpha
Integra LifeSciences Stock - Sunday background on risks and outlook
This article provides a Sunday background look at Integra LifeSciences (IART) stock, focusing on its business profile, key risks, and future outlook. It highlights past quality control issues, current valuation, and earnings expectations, noting that investors are watching remedi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Jun 2026 18:10
- Source
- AD HOC NEWS
Integra LifeSciences Holdings (IART) Stock Could Be 34.9% Undervalued After Argus Upgrade
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 21 Jun 2026 05:28
- Source
- simplywall.st
Argus upgrades Integra LifeSciences stock rating on turnaround
Argus has upgraded Integra LifeSciences Holdings (NASDAQ:IART) to Buy from Hold, setting a price target of $25.00 due to expected earnings turnaround driven by executive changes and resolution of production issues. The medical technology company exceeded Q1 EPS expectations and r
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 18 Jun 2026 20:39
- Source
- Investing.com
Integra LifeSciences (IART) Upgraded to Buy with Positive Outloo
- Tone
- Positive 95/100
- Event
- Analyst action
- Published
- 18 Jun 2026 16:45
- Source
- GuruFocus
Argus upgrades Integra LifeSciences stock rating on turnaround By Investing.com
Argus has upgraded Integra LifeSciences Holdings (NASDAQ:IART) stock rating to Buy from Hold, setting a price target of $25.00. The upgrade is attributed to executive changes, resolved production issues, and an expected earnings turnaround, along with consistent growth. Integra L
- Tone
- Positive 71/100
- Event
- Analyst action
- Published
- 18 Jun 2026 13:09
- Source
- Investing.com Canada
Argus Research Upgrades Integra LifeSciences to Buy From Hold, $25 Price Target
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 18 Jun 2026 11:57
- Source
- MT Newswires
Integra Lifesciences Holdings Corp (IART) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides a detailed revenue breakdown for Integra Lifesciences Holdings Corp (IART) by business segment and geographical region. It shows that Neurosurgery accounts for over 50% of its revenue, and the United States contributes the largest share regionally. The data
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 00:41
- Source
- TradingKey
Integra Lifesciences Holdings Corp (IART) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Integra Lifesciences Holdings Corp (IART), listing its major institutional holders and their respective proportions. It also presents a breakdown of shareholder types, including investment advisors, hedge funds, and individual inv
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 21:41
- Source
- TradingKey
Integra Lifesciences Holdings Corp (IART) Earnings Forecast: Future EPS & Revenue Growth Estimates
Integra Lifesciences Holdings Corp (IART) has an earnings forecast score of 5.80, ranking 185 out of 203 in its industry. Analysts have set an average price target of $13.00, with a range from $10.00 to $25.00, and a general "Hold" rating. The company's expected revenue for the n
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 12:40
- Source
- TradingKey
Does Earnings Beat And MedTech Spotlight Reframe The Bull Case For Integra LifeSciences (IART)?
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 17 Jun 2026 04:54
- Source
- simplywall.st
Integra Lifesciences Holdings Corp (IART) Institutional Confidence
Integra Lifesciences Holdings Corp (IART) has an institutional shareholding score of 10.00, ranking 1st in the Healthcare Equipment & Supplies industry. Institutional holdings increased by 10.94% quarter-over-quarter, with 106.43% of shares held by institutions. ETHSX is the larg
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 16 Jun 2026 19:40
- Source
- TradingKey
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jun 2026 14:49
- Source
- Market source
Integra LifeSciences Holdings Corporation (IART) Hits Fresh High: Is There Still Room to Run?
Integra LifeSciences Holdings Corporation (IART) has recently reached a new 52-week high, with its stock up 23.7% in the past month and 40.6% year-to-date. The company has consistently beaten earnings estimates, reporting EPS of $0.54 against a consensus of $0.41 in its last repo
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 16 Jun 2026 13:39
- Source
- Market source
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
Integra LifeSciences Holdings Corporation announced that Bob Davis, executive vice president and president of Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference on June 16, 2026, at 3:00 PM ET. A live webcast of the presentation will be available
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 19:10
- Source
- Market source
Live webcast of Integra Truist MedTech talk set for June 16
Integra LifeSciences (Nasdaq: IART) announced that Bob Davis, executive vice president and president Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference on June 16, 2026, at 3:00pm ET. A live webcast of the presentation will be available on the co
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 12:40
- Source
- Stock Titan
Medical Devices & Supplies - Specialty Stocks Q1 Earnings: STAAR Surgical (NASDAQ:STAA) Firing on All Cylinders
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Jun 2026 07:00
- Source
- The Globe and Mail
Integra LifeSciences stock hits 52-week high at 17.84 USD
Integra LifeSciences Holdings (IART) stock has reached a 52-week high at $17.84, driven by impressive year-to-date gains of 36.39% and strong first-quarter 2026 financial results that surpassed analyst expectations. The company reported adjusted earnings per share of $0.54 and re
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 09 Jun 2026 15:11
- Source
- Investing.com
A Look At Integra LifeSciences Holdings (IART) Valuation After Its Recent Share Price Rebound
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jun 2026 07:00
- Source
- simplywall.st
Integra LifeSciences (IART) EPS Beat and Conference Push: What Does It Reveal About Management’s Conviction?
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 06 Jun 2026 02:12
- Source
- Simply Wall St.
Why Is Integra (IART) Up 15% Since Last Earnings Report?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jun 2026 07:00
- Source
- Market source
Integra (IART) EVP awarded RSUs and stock options in new grant
Michael J. McBreen, EVP & Chief Commercial Officer at Integra LifeSciences Holdings Corp (IART), was granted 31,909 restricted stock units and a non-qualified stock option for 60,372 shares with an exercise price of $15.67. Both awards vest in three equal annual installments, con
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 21:09
- Source
- Stock Titan
Integra (IART) CEO receives new RSU and stock option grants
Integra LifeSciences Holdings Corp (IART) CEO Stuart Essig was granted 365,297 Restricted Stock Units (RSUs) and 705,468 non-qualified stock options on June 1, 2026. These awards, part of his employment agreement and at the discretion of the Compensation Committee, will vest over
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 21:09
- Source
- Stock Titan
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Integra LifeSciences (IART) Investors of Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm's Attorneys
Hagens Berman is reminding investors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) about a pending securities fraud class action lawsuit. The lawsuit alleges that Integra made misleading statements and failed to disclose Good Manufacturing Practices violations at its Bost
- Tone
- Negative 9/100
- Event
- Regulatory and legal
- Published
- 02 Jun 2026 13:40
- Source
- TMX Newsfile
CFO Lea Knight to speak June 3 at Jefferies healthcare forum
Integra LifeSciences announced that its Chief Financial Officer, Lea Knight, will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the company's investor relations website. This pre
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 11:09
- Source
- Stock Titan
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
Integra LifeSciences Holdings Corporation announced that CFO Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website. The company
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:30
- Source
- GlobeNewswire
Integra LifeSciences Hits New 52-Week High at $16.62
Integra LifeSciences Holdings Corp. reached a new 52-week high of $16.62 on May 28, 2026, despite a significant 46.3% decline in its stock performance over the past year. The company, which operates in the Pharmaceuticals & Biotechnology sector, has a market capitalization of $74
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 31 May 2026 19:10
- Source
- Markets Mojo
Integra LifeSciences Hits Day High with 8.36% Surge in Stock Price
Integra LifeSciences Holdings Corp. experienced an 8.36% surge in its stock price, reaching an intraday high of USD 16.62. The company has shown significant short-term growth, with a 53.26% increase over the past month and 32.53% year-to-date, outperforming the S&P 500. Despite t
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 29 May 2026 19:39
- Source
- Markets Mojo
Integra LifeSciences stock (US4579851036): Citi upgrade and 52-week high put valuation back in focus
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 29 May 2026 07:00
- Source
- AD HOC NEWS